Click for best price
Metabolic Disease Drugs Market Size, Share 2022
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report contains market size and forecasts of Metabolic Disease Drugs in Global, including the following market information:
Global Metabolic Disease Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Metabolic Disease Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metabolic Disease Drugs include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Beohrigher Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Metabolic Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metabolic Disease Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Metabolic Disease Drugs Market Segment Percentages, by Type, 2021 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Metabolic Disease Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Metabolic Disease Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Global Metabolic Disease Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Metabolic Disease Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metabolic Disease Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Metabolic Disease Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
| Report Attributes |
Report Details |
| Report Title |
Metabolic Disease Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
63 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Metabolic Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metabolic Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metabolic Disease Drugs Overall Market Size
2.1 Global Metabolic Disease Drugs Market Size: 2021 VS 2028
2.2 Global Metabolic Disease Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metabolic Disease Drugs Players in Global Market
3.2 Top Global Metabolic Disease Drugs Companies Ranked by Revenue
3.3 Global Metabolic Disease Drugs Revenue by Companies
3.4 Top 3 and Top 5 Metabolic Disease Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Metabolic Disease Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metabolic Disease Drugs Players in Global Market
3.6.1 List of Global Tier 1 Metabolic Disease Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Metabolic Disease Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Metabolic Disease Drugs Market Size Markets, 2021 & 2028
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type - Global Metabolic Disease Drugs Revenue & Forecasts
4.2.1 By Type - Global Metabolic Disease Drugs Revenue, 2017-2022
4.2.2 By Type - Global Metabolic Disease Drugs Revenue, 2023-2028
4.2.3 By Type - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Metabolic Disease Drugs Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.2 By Application - Global Metabolic Disease Drugs Revenue & Forecasts
5.2.1 By Application - Global Metabolic Disease Drugs Revenue, 2017-2022
5.2.2 By Application - Global Metabolic Disease Drugs Revenue, 2023-2028
5.2.3 By Application - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Metabolic Disease Drugs Market Size, 2021 & 2028
6.2 By Region - Global Metabolic Disease Drugs Revenue & Forecasts
6.2.1 By Region - Global Metabolic Disease Drugs Revenue, 2017-2022
6.2.2 By Region - Global Metabolic Disease Drugs Revenue, 2023-2028
6.2.3 By Region - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Metabolic Disease Drugs Revenue, 2017-2028
6.3.2 US Metabolic Disease Drugs Market Size, 2017-2028
6.3.3 Canada Metabolic Disease Drugs Market Size, 2017-2028
6.3.4 Mexico Metabolic Disease Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Metabolic Disease Drugs Revenue, 2017-2028
6.4.2 Germany Metabolic Disease Drugs Market Size, 2017-2028
6.4.3 France Metabolic Disease Drugs Market Size, 2017-2028
6.4.4 U.K. Metabolic Disease Drugs Market Size, 2017-2028
6.4.5 Italy Metabolic Disease Drugs Market Size, 2017-2028
6.4.6 Russia Metabolic Disease Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Metabolic Disease Drugs Market Size, 2017-2028
6.4.8 Benelux Metabolic Disease Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Metabolic Disease Drugs Revenue, 2017-2028
6.5.2 China Metabolic Disease Drugs Market Size, 2017-2028
6.5.3 Japan Metabolic Disease Drugs Market Size, 2017-2028
6.5.4 South Korea Metabolic Disease Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Metabolic Disease Drugs Market Size, 2017-2028
6.5.6 India Metabolic Disease Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Metabolic Disease Drugs Revenue, 2017-2028
6.6.2 Brazil Metabolic Disease Drugs Market Size, 2017-2028
6.6.3 Argentina Metabolic Disease Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Metabolic Disease Drugs Revenue, 2017-2028
6.7.2 Turkey Metabolic Disease Drugs Market Size, 2017-2028
6.7.3 Israel Metabolic Disease Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Metabolic Disease Drugs Market Size, 2017-2028
6.7.5 UAE Metabolic Disease Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Merck
7.1.1 Merck Corporate Summary
7.1.2 Merck Business Overview
7.1.3 Merck Metabolic Disease Drugs Major Product Offerings
7.1.4 Merck Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.1.5 Merck Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Metabolic Disease Drugs Major Product Offerings
7.2.4 Novartis Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.2.5 Novartis Key News
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Corporate Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Major Product Offerings
7.3.4 Takeda Pharmaceutical Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.3.5 Takeda Pharmaceutical Key News
7.4 Astra Zeneca
7.4.1 Astra Zeneca Corporate Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Metabolic Disease Drugs Major Product Offerings
7.4.4 Astra Zeneca Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.4.5 Astra Zeneca Key News
7.5 Beohrigher Ingelheim
7.5.1 Beohrigher Ingelheim Corporate Summary
7.5.2 Beohrigher Ingelheim Business Overview
7.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Major Product Offerings
7.5.4 Beohrigher Ingelheim Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.5.5 Beohrigher Ingelheim Key News
7.6 KOWA
7.6.1 KOWA Corporate Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Metabolic Disease Drugs Major Product Offerings
7.6.4 KOWA Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.6.5 KOWA Key News
7.7 Kythera
7.7.1 Kythera Corporate Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Metabolic Disease Drugs Major Product Offerings
7.7.4 Kythera Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.7.5 Kythera Key News
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Corporate Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Metabolic Disease Drugs Major Product Offerings
7.8.4 Fuji yakuhin Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.8.5 Fuji yakuhin Key News
7.9 LG Life Science
7.9.1 LG Life Science Corporate Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Metabolic Disease Drugs Major Product Offerings
7.9.4 LG Life Science Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.9.5 LG Life Science Key News
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Corporate Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue in Global Market (2017-2022)
7.10.5 Metsubishi Tanabe Pharma Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Metabolic Disease Drugs Market Opportunities & Trends in Global Market
Table 2. Metabolic Disease Drugs Market Drivers in Global Market
Table 3. Metabolic Disease Drugs Market Restraints in Global Market
Table 4. Key Players of Metabolic Disease Drugs in Global Market
Table 5. Top Metabolic Disease Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Metabolic Disease Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Metabolic Disease Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Metabolic Disease Drugs Product Type
Table 9. List of Global Tier 1 Metabolic Disease Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metabolic Disease Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Metabolic Disease Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Metabolic Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Metabolic Disease Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Metabolic Disease Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Metabolic Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Metabolic Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Metabolic Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Metabolic Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Merck Corporate Summary
Table 31. Merck Metabolic Disease Drugs Product Offerings
Table 32. Merck Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Metabolic Disease Drugs Product Offerings
Table 35. Novartis Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Takeda Pharmaceutical Corporate Summary
Table 37. Takeda Pharmaceutical Metabolic Disease Drugs Product Offerings
Table 38. Takeda Pharmaceutical Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Astra Zeneca Corporate Summary
Table 40. Astra Zeneca Metabolic Disease Drugs Product Offerings
Table 41. Astra Zeneca Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Beohrigher Ingelheim Corporate Summary
Table 43. Beohrigher Ingelheim Metabolic Disease Drugs Product Offerings
Table 44. Beohrigher Ingelheim Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 45. KOWA Corporate Summary
Table 46. KOWA Metabolic Disease Drugs Product Offerings
Table 47. KOWA Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Kythera Corporate Summary
Table 49. Kythera Metabolic Disease Drugs Product Offerings
Table 50. Kythera Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Fuji yakuhin Corporate Summary
Table 52. Fuji yakuhin Metabolic Disease Drugs Product Offerings
Table 53. Fuji yakuhin Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 54. LG Life Science Corporate Summary
Table 55. LG Life Science Metabolic Disease Drugs Product Offerings
Table 56. LG Life Science Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Metsubishi Tanabe Pharma Corporate Summary
Table 58. Metsubishi Tanabe Pharma Metabolic Disease Drugs Product Offerings
Table 59. Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Metabolic Disease Drugs Segment by Type in 2021
Figure 2. Metabolic Disease Drugs Segment by Application in 2021
Figure 3. Global Metabolic Disease Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Metabolic Disease Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Metabolic Disease Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metabolic Disease Drugs Revenue in 2021
Figure 8. By Type - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 12. US Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 24. China Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Metabolic Disease Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Metabolic Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Merck Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Takeda Pharmaceutical Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Astra Zeneca Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Beohrigher Ingelheim Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. KOWA Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kythera Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Fuji yakuhin Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. LG Life Science Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
